Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Kelly McGlinchey"'
Autor:
Mark Cobbold, Gordon Moody, Kelly McGlinchey, Emily Bosco, Peter Zanvit, Christine Fazenbaker, Weichuan Luo, Jessica Pezold, Clare Hoover
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/e5e673da0a984d5aafd7bab7e39bcc6a
Autor:
Peter Zanvit, Dewald van Dyk, Christine Fazenbaker, Kelly McGlinchey, Weichuan Luo, Jessica M. Pezold, John Meekin, Chien-ying Chang, Rosa A. Carrasco, Shannon Breen, Crystal Sao-Fong Cheung, Ariel Endlich-Frazier, Benjamin Clark, Nina J. Chu, Alessio Vantellini, Philip L. Martin, Clare E. Hoover, Kenesha Riley, Steve M. Sweet, David Chain, Yeoun Jin Kim, Eric Tu, Nathalie Harder, Sandrina Phipps, Melissa Damschroder, Ryan N. Gilbreth, Mark Cobbold, Gordon Moody, Emily E. Bosco
Publikováno v:
The Journal of Clinical Investigation, Vol 133, Iss 22 (2023)
Prostate cancer is generally considered an immunologically “cold” tumor type that is insensitive to immunotherapy. Targeting surface antigens on tumors through cellular therapy can induce a potent antitumor immune response to “heat up” the tu
Externí odkaz:
https://doaj.org/article/e772d4b790a848fcb94aa4259efad645
Autor:
Eric Tu, Kelly McGlinchey, Jixin Wang, Philip Martin, Steven L.K. Ching, Nicolas Floc’h, James Kurasawa, Jacqueline H. Starrett, Yelena Lazdun, Leslie Wetzel, Barrett Nuttall, Felicia S.L. Ng, Karen T. Coffman, Paul D. Smith, Katerina Politi, Zachary A. Cooper, Katie Streicher
Publikováno v:
JCI Insight, Vol 7, Iss 3 (2022)
Treatment with anti–PD-1 and anti-PD-L1 therapies has shown durable clinical benefit in non–small cell lung cancer (NSCLC). However, patients with NSCLC with epidermal growth factor receptor (EGFR) mutations do not respond as well to treatment as
Externí odkaz:
https://doaj.org/article/c6a5fda9646e49b8adcbb817d655948e
Autor:
Darren J. Schofield, Jennifer Percival-Alwyn, Mateusz Rytelewski, John Hood, Raymond Rothstein, Leslie Wetzel, Kelly McGlinchey, Grace Adjei, Amanda Watkins, LeeAnn Machiesky, Weimin Chen, John Andrews, Maria Groves, Michelle Morrow, Ross A. Stewart, Andrew Leinster, Robert W. Wilkinson, Scott A. Hammond, Nadia Luheshi, Claire Dobson, Michael Oberst
Publikováno v:
mAbs, Vol 13, Iss 1 (2021)
Preclinical studies of PD-L1 and CTLA-4 blockade have relied heavily on mouse syngeneic tumor models with intact immune systems, which facilitate dissection of immunosuppressive mechanisms in the tumor microenvironment. Commercially developed monoclo
Externí odkaz:
https://doaj.org/article/5b7084f79f5a4c06ad3eff39bdaa115c
Autor:
Nick M. Durham, Nick Holoweckyj, Randall S. MacGill, Kelly McGlinchey, Ching Ching Leow, Scott H. Robbins
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 5, Iss 1, Pp 1-12 (2017)
Abstract Background The expansion of antigen-specific CD8 T cells is important in generating an effective and long-lasting immune response to tumors and viruses. Glucocorticoid-induced tumor necrosis factor receptor family-related receptor (GITR) is
Externí odkaz:
https://doaj.org/article/c0411b30dc4c45a186da0ada7b815816
Autor:
Jonathan W. Goldman, Sarina A. Piha-Paul, Brendan Curti, Katrina S. Pedersen, Todd M. Bauer, Stefanie L. Groenland, Richard D. Carvajal, Vaishali Chhaya, Gray Kirby, Kelly McGlinchey, Scott A. Hammond, Katie Streicher, Danielle M. Townsley, Young Kwang Chae, Jens Voortman, Aurelien Marabelle, John Powderly
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, 28(17), 3709-3719. American Association for Cancer Research Inc.
Goldman, J W, Piha-Paul, S A, Curti, B, Pedersen, K S, Bauer, T M, Groenland, S L, Carvajal, R D, Chhaya, V, Kirby, G, McGlinchey, K, Hammond, S A, Streicher, K, Townsley, D M, Chae, Y K, Voortman, J, Marabelle, A & Powderly, J 2022, ' Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors ', Clinical cancer research : an official journal of the American Association for Cancer Research, vol. 28, no. 17, pp. 3709-3719 . https://doi.org/10.1158/1078-0432.CCR-21-3016
Goldman, J W, Piha-Paul, S A, Curti, B, Pedersen, K S, Bauer, T M, Groenland, S L, Carvajal, R D, Chhaya, V, Kirby, G, McGlinchey, K, Hammond, S A, Streicher, K, Townsley, D M, Chae, Y K, Voortman, J, Marabelle, A & Powderly, J 2022, ' Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors ', Clinical cancer research : an official journal of the American Association for Cancer Research, vol. 28, no. 17, pp. 3709-3719 . https://doi.org/10.1158/1078-0432.CCR-21-3016
Purpose: Combination therapies targeting immunologic checkpoints have shown promise in treating multiple tumor types. We report safety and tolerability of MEDI0562, a humanized IgG1K OX40 mAb, in combination with durvalumab (anti-PD-L1), or tremelimu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc2ae1dee17b1c4274c5fa067c0313f8
https://doi.org/10.1158/1078-0432.ccr-21-3016
https://doi.org/10.1158/1078-0432.ccr-21-3016
Autor:
Scott A. Hammond, Andrew Weinberg, Nicholas P. Morris, Louis Picker, Michael K. Axthelm, Andrew Sylwester, Haesun Park, Andrew J. Pierce, Lolke de Haan, Nicholas Buss, Steven Eck, Hui Feng, Melissa Damschroder, Qun Du, Shino Hanabuchi, James Hair, Kelly McGlinchey, Kathy Mulgrew, Stacy Kentner, Chad Morris, Catherine Augé, Michael D. Oberst
Expression of cell surface Fc gamma receptors on human cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::123f7d8216dfd0b1f3ce6f1f64cd89ab
https://doi.org/10.1158/1535-7163.22505539.v1
https://doi.org/10.1158/1535-7163.22505539.v1
Autor:
Scott A. Hammond, Andrew Weinberg, Nicholas P. Morris, Louis Picker, Michael K. Axthelm, Andrew Sylwester, Haesun Park, Andrew J. Pierce, Lolke de Haan, Nicholas Buss, Steven Eck, Hui Feng, Melissa Damschroder, Qun Du, Shino Hanabuchi, James Hair, Kelly McGlinchey, Kathy Mulgrew, Stacy Kentner, Chad Morris, Catherine Augé, Michael D. Oberst
Supplementary Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae534900ee576be4839bebdf0965290a
https://doi.org/10.1158/1535-7163.22505521
https://doi.org/10.1158/1535-7163.22505521
Autor:
Scott A. Hammond, Andrew Weinberg, Nicholas P. Morris, Louis Picker, Michael K. Axthelm, Andrew Sylwester, Haesun Park, Andrew J. Pierce, Lolke de Haan, Nicholas Buss, Steven Eck, Hui Feng, Melissa Damschroder, Qun Du, Shino Hanabuchi, James Hair, Kelly McGlinchey, Kathy Mulgrew, Stacy Kentner, Chad Morris, Catherine Augé, Michael D. Oberst
Ligation of OX40 (CD134, TNFRSF4) on activated T cells by its natural ligand (OX40L, CD252, TNFSF4) enhances cellular survival, proliferation, and effector functions such as cytokine release and cellular cytotoxicity. We engineered a recombinant huma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b9055300403acf6ff9ac96ec905dac3f
https://doi.org/10.1158/1535-7163.c.6538102.v1
https://doi.org/10.1158/1535-7163.c.6538102.v1
Autor:
Scott A. Hammond, Andrew Weinberg, Nicholas P. Morris, Louis Picker, Michael K. Axthelm, Andrew Sylwester, Haesun Park, Andrew J. Pierce, Lolke de Haan, Nicholas Buss, Steven Eck, Hui Feng, Melissa Damschroder, Qun Du, Shino Hanabuchi, James Hair, Kelly McGlinchey, Kathy Mulgrew, Stacy Kentner, Chad Morris, Catherine Augé, Michael D. Oberst
Supplementary Figure 5. Lack of NK cell mediated ADCC and complement protein C1q binding by MEDI6383. Supplementary Figure 6. MEDI6383 mediated release of cytokines from primary human T cells.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db041ff2d652c7052f608239ed819b86
https://doi.org/10.1158/1535-7163.22505527.v1
https://doi.org/10.1158/1535-7163.22505527.v1